Dec 29 (Reuters) - Ultragenyx Pharmaceutical said on Monday that its experimental drug for a type of genetic bone disease did not meet the main goal in late-stage studies. The company was testing the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results